COVID-19

Bharat Biotech, a global leader in vaccine innovation and developer of vaccines for infectious diseases has dedicated iNCOVACC® (BBV154) to the nation, world’s 1st COVID intranasal vaccine for Primary series and Heterologous booster. iNCOVACC® is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein. This vaccine candidate was evaluated in phase I, II and III clinical trials with successful results. Product development and...

India Sees a gradual rise in Covid Cases Due to a new Covid Variant BF.7. The current wave of Covid cases in India has been attributed to the Omicron sub-variant, BF.7. According to virology logic, BF.7 should be more infectious than Omicron but less fatal. This follows the pattern of viruses adapting and mutating over time to become more transmissible and less lethal in...

Hyderabad, Dec 27, 2022: Bharat Biotech iNCOVACC® (BBV154),the nasal vaccine for covid-19 is scheduled to be introduced in the country as a booster dose shortly. iNCOVACC® is now available on CoWin, and priced at INR 800 for private markets and priced at INR 325 for supplies to Govt of India and State Governments. The price is exclusive of GST. Earlier this month, Bharat Biotech received...

Indians' will soon have access to Bharat Biotech's covid-19 nasal vaccine "iNCOVACC" . Health Minister Dr Mansukh Mandaviya said that Bharat biotech nasal vaccine has been approved and will soon be added in CoWIN app. The Covid-19 vaccine has received the approval for use as a booster dose -Dr Mansukh Mandaviya said. Bharat Biotech's intranasal Covid vaccine will be available in private centres and will...

Coronavirus News: Covid is Not Over Yet - warns the Indian Health Minister. His statement came in response to the increasing number of Covid-19 cases in China, Union Health Minister Mansukh Mandaviya stated that he had reviewed the country's coronavirus situation with experts and officials, added that Covid-19 was still present, and instructed all relevant officials to remain vigilant and to step up surveillance. "In...

Bharat Biotech iNCOVACC®️ (BBV154), has received approval from the Central Drugs Standard Control Organisation (CDSCO) under Restricted Use in Emergency Situation for ages 18 and above, in India, for heterologous booster doses. In heterologous boosting, a person administered a different vaccine from the one that was used for the primary dose series. Key Facts about iNCOVACC Vaccine iNCOVACC®️ is the world’s first Intranasal vaccine for COVID to...

9 million doses of Moderna will be disposed of in Switzerland (MRNA.O) The government announced  that 5.1 million doses of COVID-19 vaccine that have passed their expiration date will follow suit by February. The wastage is a result of Switzerland's decision to acquire more vaccines than was necessary to ensure that its population of 8.7 million people would have access to enough doses even...

Here is a good news for international travelers travelling to Canada. Canada stated has revised its visitor entry rules, and announced that visitors from outside Canada will no longer need the Covid-19 vaccination in order to enter the land of maple syrup. The removal of border measures has been facilitated by a number of factors, including modelling that indicates that Canada has largely passed the...

Bharat Biotech's intra nasal vaccine iNCOVACC (BBV154), has received approval under Restricted Use in Emergency Situation for ages 18 and above in India. This is World's First Intranasal Vaccines to receive approvals for Primary 2 dose schedule . Highlights of Bharat Biotech Intra Nasal Vaccine - iNCOVACC iNCOVACC receives approval under Restricted Use in Emergency Situations for ages 18 and above.Bharat Biotech is a global leader in...

On Friday, mRNA vaccine developer Moderna filed a patent infringement lawsuit against Pfizer and its German partner BioNTech over the development of the first COVID-19 vaccine approved in the United States, claiming that the defendants stole technology that Moderna had developed years before the pandemic. Moderna in a tweet wrote, Moderna is filing the suit against Pfizer and BioNTech, alleging infringement of patents central to Moderna’s...